Labiotech.eu - Europe's leading Biotech News Website

Latest Posts

Cardior Pharmaceuticals fundraising

News and Trends 12 May 2017

German Biotech Raises €15M to Treat Heart Failure with Non-coding RNA

Cardior Pharmaceuticals will use the funds to develop an innovative technology based on non-coding RNAs involved in cardiac remodeling. Founded less than a year ago, Cardior Pharmaceuticals is dedicated to developing a novel technology to predict and treat heart failure. In such a short timeframe, the German biotech has managed to attract some of the best […]

May 12, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

fossil proteins virus resistance granada

News and Trends 12 May 2017

Resurrected Proteins could be New Weapon against Crop Viruses

Researchers from Spain have succeeded in expressing a 4 billion year-old enzyme in a present-day E. coli. It’s similar enough to the modern version to work, but different enough to dupe viruses. A new way to create virus resistance in crops? In a lab at the University of Granada, Spain, that specializes in reconstructing ancient gene sequences, researchers have […]

May 12, 2017 - 3 minutesmins - By Denise Neves Gameiro

shutterstock 491203939

News and Trends 12 May 2017

UPDATE: Italian Pharma receives €11M for Parkinson’s Drug Approval

UPDATE (12/05/2017): Newron has received €11.3M as a milestone payment for the approval from its partner, Zambon, which has the rights to commercialise Xadago globally. Originally published on 21/04/2017 Newron, an Italian biotech focused on CNS diseases, is on a roll. The latest win? FDA approval of its Parkinson’s drug, Xadago. Just in time for World […]

May 12, 2017 - 2 minutesmins - By Evelyn Warner

Celyad heart failure cell therapy C Cure

News and Trends 11 May 2017

Celyad gets FDA Fast Track to Tackle Heart Failure with Cell Therapy

Celyad has received Fast Track Designation from the FDA for C-Cure, a cell therapy aimed to treat heart failure with the patient’s own stem cells. Celyad is confident that the announcement of Fast Track Designation from the FDA will help it accelerate the search for a partner to develop C-Cure, a cell therapy for ischemic […]

May 11, 2017 - 1 minutemin - By Clara Rodríguez Fernández

raffi thumbnail youtube 720

Interview 11 May 2017

Video: Meet the CEO developing Gene Therapy without Viral Vectors

Eyevensys has found a way to deliver gene therapy without viral vectors. Clara caught up with the company’s CEO Raffy Kazandjian at BioTrinity to hear more. Eyevensys is based in Paris and has set itself the mission of enhancing current treatment options in the field of ophthalmology. The biotech has developed a new gene therapeutic approach that […]

May 11, 2017 - 2 minutesmins - By Melanie De Almeida

Study HIV Life Expectancy

News and Trends 11 May 2017

HIV Treatment Development Extends Life Expectancy by 10 Years

According to a new study, the life expectancy of 20-year-olds starting HIV treatment has increased by a decade in the EU and North America. A massive new study from the UK was published today in The Lancet HIV. The study tracked how many HIV patients died during the first three years of HIV treatment, their cause […]

May 11, 2017 - 3 minutesmins - By Melanie De Almeida

ADVERTISEMENT

shutterstock 620087714

News and Trends 10 May 2017

Oxford Synbio Startup with Eyes on Therapeutics gets hold of CRISPR

Synbio startup Oxford Genetics has licensed CRISPR from Emmanuelle Charpentier’s company, ERS Genomics, to boost its platform. Synthetic biology has so far remained on the fringe of biotech, but one company, Oxford Genetics, is demonstrating its use in therapeutics. To bolster its efforts, the startup has secured a nonexclusive license from ERS Genomics, which represents […]

May 10, 2017 - 2 minutesmins - By Evelyn Warner

Roche tecentriq bladder cancer fail

News and Trends 10 May 2017

Roche’s Checkpoint Inhibitor Misfires in Late-Stage Trials

Roche’s drug tecentriq just failed a late-stage Phase III study in bladder cancer, raising questions about its future as an anticipated blockbuster. Roche and Genentech have been pushing their checkpoint inhibitor tecentriq onto the market last year, going for a number of different indications including bladder cancer and non-small cell lung cancer (NSCLC). After the FDA handed out accelerated approval in May 2016, […]

May 10, 2017 - 3 minutesmins - By Melanie De Almeida

linda summerton thumbnail youtube 720

Interview 10 May 2017

Video: Meet the CEO fighting Cancer with Mycobacteria

Clara talked to Linda Summerton, CEO of Immodulon Therapeutics, about the company’s project of applying the microbiome to immuno-oncology. As R&D efforts in the microbiome gain traction, Clara talked to the head of one of the most valuable companies in the UK, Immodulon Therapeutics. When asked about Forbes’ valuation of her company at £400M, Linda Summerton laughed, “That’s […]

May 10, 2017 - 3 minutesmins - By Evelyn Warner

In Depth 10 May 2017

Incentivizing Charity: A New Way to Fund Cancer Research

Here’s what we learned from a lecture by finance guru Roger Stein on a new cancer research funding model at the Charité BIH Entrepreneurship Summit in Berlin. “I’m not a scientist. I can’t build a drug. I’m never going to have enough money to fund even one of those [clinical] trials. But…all of us together […]

May 10, 2017 - 4 minutesmins - By Evelyn Warner

microbiome genetics expert panel

News and Trends 10 May 2017

Experts say the Microbiome could overtake Genetics as the Next Big Thing

Yesterday, a panel of experts at BioTrinity discussed the huge possibilities offered by the young microbiome field, which could soon overtake genetics. Scientists and investors worldwide are starting to turn to the microbiome, which many believe hold the key to human health. The microorganisms that live in us and on us have shown to play […]

May 10, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

Adam Stoten thumbnail youtube11

Interview 9 May 2017

Video Interview: Meet the Oxford COO improving Tech Transfer

Adam Stoten is the new COO of Oxford University Innovation. Philip caught up with him at BioTrinity in London to talk about tech transfer. Both from academic and industrial perspectives, tech transfer has a reputation for being an onerous process. But some organizations are working steadfastly to streamline it with great success, like Oxford University Innovation. […]

May 9, 2017 - 2 minutesmins - By Evelyn Warner

ADVERTISEMENT